News

On May 12, at the European Medicines Verification Organisation’s (EMVO) General Assembly meeting, the NMVO Observers within EMVO’s Board for 2023 from the National Medicines Verification Organizations (NMVOs) were approved. As one of the observers representing the group of small-scale countries, will be the Latvian Medicines Verification Organisation (LZVO) and its Chairwoman of the Board Inese Erdmane.

The European Medicines Verification Organisation (EMVO) has launched a newsletter, which looks back on the past four years of the verification system’s operation, informs about the launch of the European Alert Management System (EAMS) and provides an opportunity to look into the first European Medicines Verification System’s (EMVS) forum, which was also attended by the Latvian Medicines Verification Organisation (LZVO) representatives Inese Erdmane and Andra Pučko.

Summarizing what was done in 2022 and outlining the plans for 2023, the European Medicines Verification Organisation (EMVO) in cooperation with the National Medicines Verification Organisations has published the EMVS Community Newsletter – 2022 Holiday Bulletin edition. In this bulletin, Inese Erdmane, Chairwoman of the Board at the Latvian Medicines Verification Organisation (LZVO), also talks about this year's achievements.

The European Medicines Verification Organization (EMVO) has launched a Newsletter, which introduces to the criteria that allow the identification of the "critical countries" of the system, tells about Romania's verification experience and other current issues of the system.

The European Medicines Verification Organization (EMVO) has launched a newsletter, which informs about the National Medicines Verification Organization (NMVO) and the European Change Control Board (EU CCB) created by the EMVO, various working groups – IT, quality, as well as the Inter-Operability Testing group, which allows for more efficient management of the medicines verification system and improvement of its development in all Member States.

The European Commission has published a new version of the Questions & Answers (Q&A) document on “Safety Features for Medicinal Products for Human Use (V.20)”.